The estimated Net Worth of Thomas G Auchincloss is at least $279 Тысяча dollars as of 6 June 2022. Mr. Auchincloss owns over 6,000 units of Concert Pharmaceuticals Inc stock worth over $147,521 and over the last 10 years he sold CNCE stock worth over $0. In addition, he makes $131,807 as Independent Director at Concert Pharmaceuticals Inc.
Thomas has made over 6 trades of the Concert Pharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 6,000 units of CNCE stock worth $28,500 on 6 June 2022.
The largest trade he's ever made was buying 6,000 units of Concert Pharmaceuticals Inc stock on 6 June 2022 worth over $28,500. On average, Thomas trades about 781 units every 139 days since 2014. As of 6 June 2022 he still owns at least 17,625 units of Concert Pharmaceuticals Inc stock.
You can see the complete history of Mr. Auchincloss stock trades at the bottom of the page.
Thomas G. Auchincloss Jr. serves as Independent Director of the Company. Mr. Auchincloss has served as a member of our Board since December 2014. Since September 2013, Mr. Auchincloss has served as Managing Member at Counterpoint Trading Company, LLC, a private investment firm. From August 2007 to September 2013, Mr. Auchincloss was self-employed in private investing. From May 2005 to August 2007, Mr. Auchincloss worked as Chief Financial Officer of Metabolix, Inc., a public biomaterials company. Prior to that, Mr. Auchincloss served as a consultant with Metabolix from April 2002 to May 2005, providing business development, financial and strategic consulting services. From 1994 to 2001, Mr. Auchincloss served in a variety of positions at Vertex Pharmaceuticals Incorporated, a pharmaceutical company, most recently as Vice President, Finance and Treasurer. Mr. Auchincloss received a B.S. in Business Administration from Babson College and an M.B.A. in Finance from the Wharton School.
As the Independent Director of Concert Pharmaceuticals Inc, the total compensation of Thomas Auchincloss at Concert Pharmaceuticals Inc is $131,807. There are 8 executives at Concert Pharmaceuticals Inc getting paid more, with Roger Tung having the highest compensation of $2,772,350.
Thomas Auchincloss is 58, he's been the Independent Director of Concert Pharmaceuticals Inc since 2017. There are 11 older and 4 younger executives at Concert Pharmaceuticals Inc. The oldest executive at Concert Pharmaceuticals Inc is Peter Hutt, 85, who is the Independent Director.
Thomas's mailing address filed with the SEC is C/O CONCERT PHARMACEUTICALS, INC., 65 HAYDEN AVENUE, SUITE 3000N, LEXINGTON, MA, 02421.
Over the last 11 years, insiders at Concert Pharmaceuticals Inc have traded over $69,766,120 worth of Concert Pharmaceuticals Inc stock and bought 1,926,078 units worth $25,219,472 . The most active insiders traders include Plc Gsk, Associates Gp Llcqvt Fund V... и Partners L P/Ilbiotechnolog.... On average, Concert Pharmaceuticals Inc executives and independent directors trade stock every 28 days with the average trade being worth of $447,820. The most recent stock trade was executed by Nancy Stuart on 15 February 2023, trading 6,048 units of CNCE stock currently worth $50,380.
Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert's lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates.
Concert Pharmaceuticals Inc executives and other stock owners filed with the SEC include: